Should I buy or sell Quanterix stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" QTRX shares. View QTRX analyst ratings or view top-rated stocks .

What is Quanterix's stock price target for 2024?

5 brokers have issued 1-year price objectives for Quanterix's stock. Their QTRX share price targets range from $30.00 to $34.00. On average, they anticipate the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 37.9% from the stock's current price. View analysts price targets for QTRX or view top-rated stocks among Wall Street analysts .

How have QTRX shares performed in 2023?

Quanterix's stock was trading at $13.85 on January 1st, 2023. Since then, QTRX shares have increased by 67.5% and is now trading at $23.20. View the best growth stocks for 2023 here .

When is Quanterix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our QTRX earnings forecast .

How were Quanterix's earnings last quarter?

Quanterix Co. (NASDAQ:QTRX) announced its earnings results on Monday, November, 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.14. The company earned $31.33 million during the quarter, compared to analysts' expectations of $27.79 million. Quanterix had a negative trailing twelve-month return on equity of 10.81% and a negative net margin of 33.03%.

What ETFs hold Quanterix's stock?

ETFs with the largest weight of Quanterix (NASDAQ:QTRX) stock in their portfolio include Simplify Health Care ETF (PINK) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH) . Invesco Nasdaq Future Gen 200 ETF (QQQS) .

What guidance has Quanterix issued on next quarter's earnings?

Quanterix issued an update on its FY 2023 earnings guidance on Monday, November, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $118.00 million-$120.00 million, compared to the consensus revenue estimate of $115.21 million.

What is Kevin Hrusovsky's approval rating as Quanterix's CEO?

15 employees have rated Quanterix Chief Executive Officer Kevin Hrusovsky on Glassdoor.com . Kevin Hrusovsky has an approval rating of 70% among the company's employees.

What other stocks do shareholders of Quanterix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Editas Medicine (EDIT) , Novavax (NVAX) , Akoustis Technologies (AKTS) , Advanced Micro Devices (AMD) , CRISPR Therapeutics (CRSP) , Walt Disney (DIS) , Illumina (ILMN) , Sorrento Therapeutics (SRNE) , Cisco Systems (CSCO) and Intellia Therapeutics (NTLA) .

When did Quanterix IPO?

(QTRX) raised $50 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morga and Leerink Partners served as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

Who are Quanterix's major shareholders?

Quanterix's stock is owned by a variety of institutional and retail investors. Top institutional investors include Invesco Ltd. (2.92%), Lord Abbett & CO. LLC (2.70%), FMR LLC (2.21%), Ashford Capital Management Inc. (2.11%), Platinum Investment Management Ltd. (1.76%) and Ameriprise Financial Inc. (1.68%). Insiders that own company stock include Amol Chaubal , David C Duffy, David C Duffy , David R Walt, Dawn Mattoon , E Kevin Hrusovsky , John J Fry, John J Fry , Marijn E Dekkers, Marijn E Dekkers , Mark T Roskey, Mark T Roskey , Masoud Toloue, Michael A Doyle and William P Donnelly. View institutional ownership trends .

How do I buy shares of Quanterix?

Shares of QTRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Quanterix Stock Price, News & Analysis (NASDAQ:QTRX)

$23.20

-0.40 (-1.69%)

(As of 12/6/2023 ET)

Compare

Today's Range: $22.98
▼
$24.13
50-Day Range: $19.54
▼
$27.96
52-Week Range: $10.02
▼
$28.77

Volume: 370,426 shs
Average Volume: 351,092 shs
Market Capitalization: $877.66 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $32.00

Quanterix MarketRank™ Stock Analysis

Analyst Rating: Buy
3.20 Rating Score
Upside/Downside: 37.9% Upside
$32.00 Price Target
Short Interest: Healthy
3.12% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$501,970 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.78) to ($0.69) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.49 out of 5 stars

Medical Sector

125th out of 955 stocks

Analytical Instruments Industry

6th out of 25 stocks

3.6

Analyst's Opinion

Consensus Rating
Quanterix has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $32.00, Quanterix has a forecasted upside of 37.9% from its current price of $23.20.
Amount of Analyst Coverage
Quanterix has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.12% of the float of Quanterix has been sold short.
Short Interest Ratio / Days to Cover
Quanterix has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Quanterix has recently decreased by 1.83%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Quanterix does not currently pay a dividend.
Dividend Growth
Quanterix does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for QTRX.

3.0

News and Social Media Coverage

News Sentiment
Quanterix has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Quanterix this week, compared to 1 article on an average week.
Search Interest
9 people have searched for QTRX on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Quanterix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Quanterix insiders have bought more of their company's stock than they have sold. Specifically, they have bought $501,970.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 8.20% of the stock of Quanterix is held by insiders.
Percentage Held by Institutions
86.64% of the stock of Quanterix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Quanterix are expected to grow in the coming year, from ($0.78) to ($0.69) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Quanterix is -22.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Quanterix is -22.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Quanterix has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Quanterix Stock (NASDAQ:QTRX)

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

QTRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

QTRX Stock News Headlines

December 4, 2023 | finance.yahoo.com

Here's Why Quanterix Corporation (QTRX) is a Great Momentum Stock to Buy

November 29, 2023 | finance.yahoo.com

Does Quanterix Corporation (QTRX) Have the Potential to Rally 33.74% as Wall Street Analysts Expect?

December 6, 2023 | Edge On The Street (Ad)

Energy Storage Trend Ignites Frenzy Over Vanadium Supply

As the world shifts to renewables such as wind and solar, how will we store all this energy? Vanadium batteries are the breakthrough that some experts predict will be the future of grid-scale energy storage. The problem is, only 5% of vanadium is mined in the U.S. - and China and Russia have a stranglehold on our supply.

November 28, 2023 | msn.com

Quanterix (QTRX) Price Target Increased by 6.67% to 32.64

November 13, 2023 | finance.yahoo.com

Quanterix To Participate at The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

November 13, 2023 | finance.yahoo.com

Wall Street Analysts See a 54.88% Upside in Quanterix Corporation (QTRX): Can the Stock Really Move This High?

November 9, 2023 | markets.businessinsider.com

Hold Rating on Quanterix Amid Strong Q3 Performance and Anticipated Challenges

November 9, 2023 | markets.businessinsider.com

Quanterix’s Robust Growth and Promising Alzheimer’s Diagnostics Drive Buy Rating Recommendation

December 6, 2023 | Edge On The Street (Ad)

Energy Storage Trend Ignites Frenzy Over Vanadium Supply

November 8, 2023 | finance.yahoo.com

Quanterix Corporation (NASDAQ:QTRX) Q3 2023 Earnings Call Transcript

November 7, 2023 | seekingalpha.com

Quanterix Corporation 2023 Q3 - Results - Earnings Call Presentation

November 7, 2023 | uk.finance.yahoo.com

Quanterix Releases Operating Results for Third Quarter 2023

November 6, 2023 | finance.yahoo.com

Quanterix Corp (QTRX) Raises Full-Year Revenue Expectations Following Q3 2023 Results

November 6, 2023 | seekingalpha.com

Quanterix Corporation: Going For Three In A Row

November 3, 2023 | benzinga.com

A Preview Of Quanterix's Earnings

October 30, 2023 | finance.yahoo.com

Quanterix to Report Third Quarter 2023 Financial Results on November 7, 2023

October 28, 2023 | markets.businessinsider.com

Quanterix’s Promising Position in Alzheimer’s Disease Diagnostics Market Prompts Buy Rating

October 24, 2023 | stockhouse.com

Quanterix Launches High Accuracy p-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer's Disease

October 24, 2023 | finance.yahoo.com

Quanterix Launches High Accuracy p-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer’s Disease

October 24, 2023 | finance.yahoo.com

Quanterix Announces New Agreement to Advance Blood Based Alzheimer's Disease Detection

October 23, 2023 | finance.yahoo.com

Quanterix (NASDAQ:QTRX) shareholders have earned a 110% return over the last year

October 11, 2023 | markets.businessinsider.com

Quanterix’s Competitive Edge in Alzheimer’s BBBM Field Upholds Buy Rating: An Analyst’s Perspective

October 3, 2023 | finance.yahoo.com

Quanterix (QTRX): A Closer Look at Its Modestly Undervalued Status

September 28, 2023 | benzinga.com

Quanterix CEO to Speak at Goldman Sachs Alzheimer's Disease Day

September 28, 2023 | finance.yahoo.com

Quanterix CEO to Speak at Goldman Sachs Alzheimer’s Disease Day

September 28, 2023 | markets.businessinsider.com

Analyst Expectations for Quanterix's Future

September 28, 2023 | msn.com

Quanterix Corporation (QTRX) Moves 7.2% Higher: Will This Strength Last?

See More Headlines

Receive QTRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quanterix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/06/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Analytical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:QTRX
CUSIP: N/A
CIK: 1503274
Web: www.quanterix.com
Phone: (617) 301-9400
Fax: N/A
Employees: 370
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $32.00
High Stock Price Target: $34.00
Low Stock Price Target: $30.00
Potential Upside/Downside: +37.9%
Consensus Rating: Buy
Rating Score (0-4): 3.20
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.03)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-96,700,000.00
Net Margins: -33.03%
Pretax Margin: -32.47%
Return on Equity: -10.81%
Return on Assets: -8.96%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.84
Quick Ratio: 10.27

Sales & Book Value

Annual Sales: $105.52 million
Price / Sales: 8.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.69 per share
Price / Book: 2.39

Miscellaneous

Outstanding Shares: 37,830,000
Free Float: 34,728,000
Market Cap: $877.66 million
Optionable: Not Optionable
Beta: 1.27

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Masoud Toloue Ph.D. (Age 42)
President, CEO & Director
Comp: $957.03k
Dr. David R. Walt Ph.D. (Age 70)
Co-Founder, Chairman of Scientific Advisory Board & Independent Director
Comp: $47.25k
Dr. Mark T. Roskey Ph.D. (Age 63)
Senior Vice President of Strategic Partnerships
Comp: $495.03k
Mr. Michael A. Doyle (Age 67)
Executive Director of Finance
Comp: $570.14k
Ms. Vandana Sriram CPA (Age 49)
Chief Financial Officer
Mr. Daniel Pikora (Age 47)
Chief Operating Officer
Dr. David C. Duffy Ph.D. (Age 52)
Senior VP of Research & Development and CTO
Comp: $299.05k
Ms. Alexandra Phillips
Senior VP & Chief Information Officer
Ms. Laurie A. Churchill (Age 52)
Senior VP, General Counsel & Secretary
David Panzerella
Vice President of Sales

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

QTRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Quanterix stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" QTRX shares.
View QTRX analyst ratings or view top-rated stocks.
What is Quanterix's stock price target for 2024?: 5 brokers have issued 1-year price objectives for Quanterix's stock. Their QTRX share price targets range from $30.00 to $34.00. On average, they anticipate the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 37.9% from the stock's current price.
View analysts price targets for QTRX or view top-rated stocks among Wall Street analysts.
How have QTRX shares performed in 2023?: Quanterix's stock was trading at $13.85 on January 1st, 2023. Since then, QTRX shares have increased by 67.5% and is now trading at $23.20.
View the best growth stocks for 2023 here.
When is Quanterix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our QTRX earnings forecast.
How were Quanterix's earnings last quarter?: Quanterix Co. (NASDAQ:QTRX) announced its earnings results on Monday, November, 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.14. The company earned $31.33 million during the quarter, compared to analysts' expectations of $27.79 million. Quanterix had a negative trailing twelve-month return on equity of 10.81% and a negative net margin of 33.03%.
What ETFs hold Quanterix's stock?: ETFs with the largest weight of Quanterix (NASDAQ:QTRX) stock in their portfolio include Simplify Health Care ETF (PINK) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).Invesco Nasdaq Future Gen 200 ETF (QQQS).

What guidance has Quanterix issued on next quarter's earnings?: Quanterix issued an update on its FY 2023 earnings guidance on Monday, November, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $118.00 million-$120.00 million, compared to the consensus revenue estimate of $115.21 million.
What is Kevin Hrusovsky's approval rating as Quanterix's CEO?: 15 employees have rated Quanterix Chief Executive Officer Kevin Hrusovsky on Glassdoor.com. Kevin Hrusovsky has an approval rating of 70% among the company's employees.
What other stocks do shareholders of Quanterix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Editas Medicine (EDIT), Novavax (NVAX), Akoustis Technologies (AKTS), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Walt Disney (DIS), Illumina (ILMN), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and Intellia Therapeutics (NTLA).
When did Quanterix IPO?: (QTRX) raised $50 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morga and Leerink Partners served as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.
Who are Quanterix's major shareholders?: Quanterix's stock is owned by a variety of institutional and retail investors. Top institutional investors include Invesco Ltd. (2.92%), Lord Abbett & CO. LLC (2.70%), FMR LLC (2.21%), Ashford Capital Management Inc. (2.11%), Platinum Investment Management Ltd. (1.76%) and Ameriprise Financial Inc. (1.68%). Insiders that own company stock include Amol Chaubal, David C Duffy, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, John J Fry, Marijn E Dekkers, Marijn E Dekkers, Mark T Roskey, Mark T Roskey, Masoud Toloue, Michael A Doyle and William P Donnelly.
View institutional ownership trends.
How do I buy shares of Quanterix?: Shares of QTRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:QTRX) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial